bushwic investors group inc.

27 north broadway
tarrytown, new york 10591

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 10, 2014

NYS DOS ID#
4541330

County
KINGS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - BUSHWIC INVESTORS GROUP INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Goldman Eyes Spinoff of Simon, an Online Tool for Bond Sales
    Wednesday Jul 5, 2017

    Goldman Sachs Group Inc. is seeking to sell a stake in Simon, its two-year-old web app that sells complex financial products to retail investors

    Source: The Wall Street Journal: Technology: What's News
  • A Slump in Tech Stocks That Leaves Some Investors Mystified
    By LANDON THOMAS Jr. - Monday Jun 12, 2017

    Shares of Netflix, Apple and other giant technology companies that have powered a market rally have taken an uncharacteristic pause.

    Source: NYT > Home Page
  • Softbank is ‘interested’ in an Uber or Lyft investment
    By Reuters - Monday Aug 7, 2017

    (Reuters) — SoftBank Group Corp, a prolific investor in global technology startups, reported a sharp rise in quarterly profits and said it would be interested in parking funds in ride-hailing firms Uber Technologies or Lyft Inc in the future. This is the first time Softbank has publicly indicated an interest in Uber, after having so far […]

    Source: VentureBeat
  • Uber Investors Clash With Board Over Voting Power
    Monday Oct 2, 2017

    Uber Technologies Inc.’s board is bracing for a contentious battle over voting control after two investors threatened legal action ahead of a planned vote Tuesday that could upend the board and diminish the power of some of the company’s earliest shareholders.

    Source: The Wall Street Journal: Technology: What's News
  • Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
    By Ben Fidler - Monday Sep 11, 2017

    A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and partner Sanofi this morning are touting results this morning from a 1,902-patient Phase 3 study called Liberty Asthma Quest. In it, their injectable antibody drug dupilumab (Dupixent), already approved […]

    Source: Xconomy New York